Prevalence of central sensitization and somatization in adults with temporomandibular disorders—a prospective observational study

Temporomandibular disorders (TMD) comprise a group of conditions affecting the masticatory muscles, the temporomandibular joints and associated structures, often manifesting as orofacial pain and functional limitations of the mandible. Central sensitization (CS) is gaining increasing attention in research focused on pain syndromes and somatization, playing a significant role in the pain experience. This study investigates the prevalence of CS and somatization among TMD patients, analyzing their relationships with TMD diagnoses and the intensity of chronic masticatory muscle pain (MMP). A prospective observational study was conducted with 214 adult participants diagnosed with TMD, based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). The Central Sensitization Inventory (CSI) and the Somatic Symptom Scale-8 (SSS-8) were utilized to assess CS and the burden of somatic symptoms, respectively. Furthermore, the patients were assessed for MMP, and the average pain in these muscles was calculated. Statistical analysis investigated correlations between CSI and SSS-8 scores, specific TMD diagnoses and MMP intensity. Most participants did not surpass the subclinical level for CS as assessed by the CSI. Women reported higher SSS-8 scores than men, suggesting sex differences in somatic symptom reporting. No significant relationship was found between specific TMD diagnoses and levels of CS or the SSS-8. However, a significant correlation was observed between SSS-8 scores and the intensity of chronic MMP, underscoring the impact of the intensity of chronic MMP on the perception of somatic symptoms among TMD patients. Additionally, the group with subclinical levels of CS presented significantly lower SSS-8 scores than other groups. This study highlights a lower-than-expected prevalence of CS among TMD patients. Higher levels of somatization were related to higher levels of CS and greater MMP. The findings suggest that TMD management should not only address specific pain sources but also consider the broader psychosocial aspects of the disorders, especially in chronic types.

Temporomandibular disorders; Masticatory muscle pain; Orofacial pain; Central Sensitization; Somatization

[1] Ferrillo M, Giudice A, Marotta N, Fortunato F, Di Venere D, Ammendolia A, et al. Pain management and rehabilitation for central sensitization in temporomandibular disorders: a comprehensive review. International Journal of Molecular Sciences. 2022; 23: 12164.

[2] Ramos-Herrada RM, Arriola-Guillén LE, Atoche-Socola KJ, Bellini-Pereira SA, Castillo AA. Effects of botulinum toxin in patients with myofascial pain related to temporomandibular joint disorders: a systematic review. Dental and Medical Problems. 2022; 59: 271–280.

[3] Valesan LF, Da-Cas CD, Réus JC, Denardin ACS, Garanhani RR, Bonotto D, et al. Prevalence of temporomandibular joint disorders: a systematic review and meta-analysis. Clinical Oral Investigations. 2021; 25: 441–453.

[4] Wieckiewicz M, Grychowska N, Nahajowski M, Hnitecka S, Kempiak K, Charemska K, et al. Prevalence and overlaps of headaches and pain-related temporomandibular disorders among the polish urban population. Journal of Oral & Facial Pain and Headache. 2020; 34: 31–39.

[5] Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the international RDC/TMD consortium network and orofacial pain special interest group. Journal of Oral & Facial Pain and Headache. 2014; 28: 6–27.

[6] Meloto CB, Slade GD, Lichtenwalter RN, Bair E, Rathnayaka N, Diatchenko L, et al. Clinical predictors of persistent temporomandibular disorder in people with first-onset temporomandibular disorder. The Journal of the American Dental Association. 2019; 150: 572–581.e10.

[7] Bueno CH, Pereira DD, Pattussi MP, Grossi PK, Grossi ML. Gender differences in temporomandibular disorders in adult populational studies: a systematic review and meta‐analysis. Journal of Oral Rehabilitation. 2018; 45: 720–729.

[8] Ohrbach R, Dworkin SF. The evolution of TMD diagnosis: past, present, future. Journal of Dental Research. 2016; 95: 1093–1101.

[9] Wieckiewicz M, Jenca A Jr, Seweryn P, Orzeszek S, Petrasova A, Grychowska N, et al. Determination of pain intensity, pain-related disability, anxiety, depression, and perceived stress in Polish adults with temporomandibular disorders: a prospective cohort study. Frontiers in Integrative Neuroscience. 2022; 16: 1026781.

[10] Seweryn P, Orzeszek SM, Waliszewska-Prosół M, Jenča A, Osiewicz M, Paradowska-Stolarz A, et al. Relationship between pain severity, satisfaction with life and the quality of sleep in Polish adults with temporomandibular disorders. Dental and Medical Problems. 2023; 60: 609–617.

[11] Osiewicz MA, Lobbezoo F, Loster BW, Loster JE, Manfredini D. Frequency of temporomandibular disorders diagnoses based on RDC/TMD in a Polish patient population. CRANIO®. 2018; 36: 304–310.

[12] Cigdem Karacay B, Sahbaz T. Investigation of the relationship between probable sleep bruxism, awake bruxism and temporomandibular disorders using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD). Dental and Medical Problems. 2023; 60: 601–608.

[13] Fillingim RB, Slade GD, Greenspan JD, Dubner R, Maixner W, Bair E, et al. Long-term changes in biopsychosocial characteristics related to temporomandibular disorder: findings from the OPPERA study. Pain. 2018; 159: 2403–2413.

[14] Yang Y, Xu LL, Liu SS, Lu SJ, Liu LK, Zeng H, et al. Analysis of risk factors and interactions for pain in temporomandibular disorder: a cross‐sectional study. Journal of Oral Rehabilitation. 2024; 51: 1113–1122.

[15] Cayrol T, van den Broeke EN, Gerard E, Meeus M, Mouraux A, Roussel N, et al. Chronic temporomandibular disorders are associated with higher propensity to develop central sensitization: a case-control study. Pain. 2023; 164: e251–e258.

[16] Harper DE, Schrepf A, Clauw DJ. Pain mechanisms and centralized pain in temporomandibular disorders. Journal of Dental Research. 2016; 95: 1102–1108.

[17] Adams LM, Turk DC. Central sensitization and the biopsychosocial approach to understanding pain. Journal of Applied Biobehavioral Research. 2018; 23: e12125.

[18] Campi LB, Jordani PC, Tenan HL, Camparis CM, Gonçalves DA. Painful temporomandibular disorders and central sensitization: implications for management—a pilot study. International Journal of Oral and Maxillofacial Surgery. 2017; 46: 104–110.

[19] Wang XY, Zhou HR, Wang S, Liu CY, Qin GC, et al. NR2B-Tyr phosphorylation regulates synaptic plasticity in central sensitization in a chronic migraine rat model. The Journal of Headache and Pain. 2018; 19: 102.

[20] Li J, Zhang L, Xu C, Lin YH, Zhang Y, Wu HY, et al. Prolonged use of NMDAR antagonist develops analgesic tolerance in neuropathic pain via nitric oxide reduction-induced GABAergic disinhibition. Neurotherapeutics. 2020; 17: 1016–1030.

[21] Monaco A, Cattaneo R, Marci MC, Pietropaoli D, Ortu E. Central sensitization-based classification for temporomandibular disorders: a pathogenetic hypothesis. Pain Research and Management. 2017; 2017: 5957076.

[22] Lorduy KM, Liegey-Dougall A, Haggard R, Sanders CN, Gatchel RJ. The prevalence of comorbid symptoms of central sensitization syndrome among three different groups of temporomandibular disorder patients. Pain Practice. 2013; 13: 604–613.

[23] Baroni A, Severini G, Straudi S, Buja S, Borsato S, Basaglia N. Hyperalgesia and central sensitization in subjects with chronic orofacial pain: analysis of pain thresholds and EEG biomarkers. Frontiers in Neuroscience. 2020; 14: 552650.

[24] Yap AU, Kim S, Lee BM, Jo JH, Park JW. Correlates of jaw functional limitation, somatization and psychological distress among different temporomandibular disorder diagnostic subtypes. Journal of Oral Rehabilitation. 2024; 51: 287–295.

[25] Felin GC, Tagliari CVDC, Agostini BA, Collares K. Prevalence of psychological disorders in patients with temporomandibular disorders: a systematic review and meta-analysis. Journal of Prosthetic Dentistry. 2024; 132: 392–401.

[26] Takeuchi T, Hashimoto K, Koyama A, Asakura K, Hashizume M. The Association of central sensitisation with depression, anxiety, and somatic symptoms: a cross-sectional study of a mental health outpatient clinic in Japan. Life. 2024; 14: 612.

[27] Yap AU, Marpaung C. Psychological factors in temporomandibular disorders and somatization: a multidimensional analysis of personality, coping, and distress among young adults. To be published in The International Journal of Prosthodontics. 2023. [Preprint].

[28] Hashimoto K, Takeuchi T, Hiiragi M, Koyama A, Nakamura Y, Hashizume M. Utility and optimal cut-off point of the somatic symptom scale-8 for central sensitization syndrome among outpatients with somatic symptoms and related disorders. BioPsychoSocial Medicine. 2022; 16: 24.

[29] Vale Braido GVD, Svensson P, Dos Santos Proença J, Mercante FG, Fernandes G, de Godoi Gonçalves DA. Are central sensitization symptoms and psychosocial alterations interfering in the association between painful TMD, migraine, and headache attributed to TMD? Clinical Oral Investigations. 2023; 27: 681–690.

[30] International classification of orofacial pain, 1st edition (ICOP). Cephalalgia. 2020; 40: 129–221.

[31] International Network for Orofacial Pain and Related Disorders Methodology. Previously known as: international RDC/TMD consortium network. 2017. Available at: https://ubwp.buffalo.edu/rdc-tmdinternational/ (Accessed: December 2017).

[32] International Network for Orofacial Pain and Related Disorders Methodology. Diagnostic Criteria for Temporomandibular Disorders (2014). 2014. Available at: https://ubwp.buffalo.edu/rdc-tmdinternational/tmd-assessmentdiagnosis/dc-tmd/ (Accessed: December 2017).

[33] Peck CC, Goulet JP, Lobbezoo F, Schiffman EL, Alstergren P, Anderson GC, et al. Expanding the taxonomy of the diagnostic criteria for temporomandibular disorders. Journal of Oral Rehabilitation. 2014; 41: 2–23.

[34] Nugent SM, Lovejoy TI, Shull S, Dobscha SK, Morasco BJ. Associations of pain numeric rating scale scores collected during usual care with research administered patient reported pain outcomes. Pain Medicine. 2021; 22: 2235–2241.

[35] Cuesta-Vargas AI, Neblett R, Chiarotto A, Kregel J, Nijs J, van Wilgen CP, et al. Dimensionality and reliability of the central sensitization inventory in a pooled multicountry sample. The Journal of Pain. 2018; 19: 317–329.

[36] Kosińska B, Tarnacka B, Turczyn P, Gromadzka G, Malec-Milewska M, Janikowska-Hołowenko D, et al. Psychometric validation of the Polish version of the central sensitization inventory in subjects with chronic spinal pain. BMC Neurology. 2021; 21: 483.

[37] Turczyn P, Kosińska B, Janikowska-Hołoweńko D, Malec-Milewska M, Marszalec N, Maleszka P, et al. Translation and cross-cultural adaptation of the Polish central sensitization inventory. Rheumatology. 2019; 57: 129–134.

[38] Neblett R, Hartzell MM, Cohen H, Mayer TG, Williams M, Choi Y, et al. Ability of the central sensitization inventory to identify central sensitivity syndromes in an outpatient chronic pain sample. The Clinical Journal of Pain. 2015; 31: 323–332.

[39] Gierk B, Kohlmann S, Kroenke K, Spangenberg L, Zenger M, Brähler E, et al. The somatic symptom scale-8 (SSS-8): a brief measure of somatic symptom burden. JAMA Internal Medicine. 2014; 174: 399–407.

[40] Toussaint A, Hüsing P, Kohlmann S, Löwe B. Detecting DSM-5 somatic symptom disorder: criterion validity of the patient health questionnaire-15 (PHQ-15) and the somatic symptom scale-8 (SSS-8) in combination with the somatic symptom disorder-B criteria scale (SSD-12). Psychological Medicine. 2020; 50: 324–333.

[41] Alhalal E, Jackson KT. Evaluation of the Arabic version of the chronic pain grade scale: psychometric properties. Research in Nursing & Health. 2021; 44: 403–412.

[42] Alkhubaizi Q, Khalaf ME, Faridoun A. Prevalence of temporomandibular disorder-related pain among adults seeking dental care: a cross-sectional study. International Journal of Dentistry. 2022; 2022: 3186069.

[43] Kimmey BA, McCall NM, Wooldridge LM, Satterthwaite TD, Corder G. Engaging endogenous opioid circuits in pain affective processes. Journal of Neuroscience Research. 2022; 100: 66–98.

[44] Bongiovanni T, Gan S, Finlayson E, Ross JS, Harrison JD, Boscardin J, et al. Use of muscle relaxants after surgery in traditional medicare part D enrollees. Drugs Aging. 2024; 41: 615–622.

[45] Siddiqui TG, Cheng S, Gossop M, Kristoffersen ES, Grambaite R, Lundqvist C. Association between prescribed central nervous system depressant drugs, comorbidity and cognition among hospitalised older patients: a cross-sectional study. BMJ Open. 2020; 10: e038432.

[46] Bhagavati S. Autoimmune disorders of the nervous system: pathophysiology, clinical features, and therapy. Frontiers in Neurology. 2021; 12: 664664.

[47] Pimentel E, Sivalingam K, Doke M, Samikkannu T. Effects of drugs of abuse on the blood-brain barrier: a brief overview. Frontiers in Neuroscience. 2020; 14: 513.

[48] Schiffman E, Ohrbach R. Executive summary of the diagnostic criteria for temporomandibular disorders for clinical and research applications. The Journal of the American Dental Association. 2016; 147: 438–445.

[49] La Touche R, Paris-Alemany A, Hidalgo-Pérez A, López-de-Uralde-Villanueva I, Angulo-Diaz-Parreño S, Muñoz-García D. Evidence for central sensitization in patients with temporomandibular disorders: a systematic review and meta-analysis of observational studies. Pain Practice. 2018; 18: 388–409.

[50] Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, et al. Migraine. Nature Reviews Disease Primers. 2022; 8: 2.

[51] Yücel FN, Duruöz MT. Central sensitization in axial spondyloarthritis: an explorative study with quantitative sensory testing and clinical scales. Modern Rheumatology. 2022; 32: 1137–1145.

[52] Meng H, Dai J, Li Y. Quantitative sensory testing in patients with the muscle pain subtype of temporomandibular disorder: a systemic review and meta-analysis. Clinical Oral Investigations. 2021; 25: 6547–6559.

[53] Jardim ML, Mélo AM, Melchior M. de O, Magri LV. Catastrophizing, central sensitization and chronic pain-related TMD: how is this association? Revista Gestão e Conhecimento. 2022; 16: 565–578.

[54] Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018; 129: 343–366.

[55] Casale R, Atzeni F, Bazzichi L, Beretta G, Costantini E, Sacerdote P, et al. Pain in women: a perspective review on a relevant clinical issue that deserves prioritization. Pain and Therapy. 2021; 10: 287–314.

[56] Reid MJ, Hamilton KR, Nilsson SJ, Owens MA, Phillips JL, Finan PH, et al. Elevated pain sensitivity is associated with reduced REM sleep in females with comorbid temporomandibular disorder and insomnia. Pain Medicine. 2024; 25: 434–443.

[57] Narrow WE, Clarke DE, Kuramoto SJ, Kraemer HC, Kupfer DJ, Greiner L, et al. DSM-5 field trials in the United States and Canada, part III: development and reliability testing of a cross-cutting symptom assessment for DSM-5. American Journal of Psychiatry. 2013; 170: 71–82.

[58] Volcheck MM, Graham SM, Fleming KC, Mohabbat AB, Luedtke CA. Central sensitization, chronic pain, and other symptoms: Better understanding, better management. Cleveland Clinic Journal of Medicine. 2023; 90: 245–254.